Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options

Open access
Kabacaoglu, Derya, Ciecielski, Katrin J., Ruess, Dietrich A., Algül, Hana · 2018 · Frontiers in Immunology

Abstract

Pancreatic ductal adenocarcinoma (PDAC), as the most frequent form of pancreatic malignancies, still has a dismal prognosis. Due to its late detection most patients are ineligible for surgery, and chemotherapeutic options are limited. Tumor heterogeneity and a characteristic structure with crosstalk between the cancer/malignant cells and an abundant tumor microenvironment make PDAC a very challenging puzzle to solve. So far, targeted therapies have failed to substantially improve the overall survival of PDAC patients. Immune checkpoint inhibition, as an emerging therapeutic option in cancer treatment shows promising results in different solid tumor types and hematological malignancies. However, PDAC doesn’t respond efficiently to immune checkpoint inhibitors anti PD-1 or anti CTLA-4 alone or in combination. PDAC with its immune-privileged nature, starting from the early pre-neoplastic state, seems to escape from the anti-tumor immune response unlike other entities. Different mechanisms are postulated how cancer cells achieve immune-privileged status. Among them are decreased antigenicity and impaired immunogenicity via both cancer cell intrinsic mechanisms and an augmented immunosuppressive tumor microenvironment. Here we seek to shed light on the recent advances in both bench and bedside investigation of immunotherapeutic options for PDAC. Besides, we aim to compile recent data about how PDAC adopts immune escape mechanisms, and how these mechanisms might be exploited therapeutically in combination with immune checkpoint inhibitors such as PD-1 or CTLA-4 antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2018.01878

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 96 references

Cited by

Metadata

Authors
Kabacaoglu, D., Ciecielski, K. J., Ruess, D. A., & Algül, H.
Venue
Frontiers in Immunology
Published
2018-08-15
Volume
9
Pages
1878-1878
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2887205254
Cited by
179
References
96
FWCI
5.48
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.